Navigation Links
Labopharm Reports Results for Second Quarter Fiscal 2009
Date:8/7/2009

.35 per share, for the first half of fiscal 2008. The decrease in net loss was primarily the result of lower research and development costs, higher gross margin on product sales and a higher foreign exchange gain, which were partially offset by higher selling, general and administrative expenses and lower interest income in the first half of fiscal 2009.

Conference Call

Labopharm will host a conference call today (Friday, August 7, 2009) at 8:30 a.m. ET to discuss its second quarter results. To access the conference call by telephone, dial 416-644-3427 or 1-800-588-4490. Please connect approximately five minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, August 14, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21311012 followed by the number sign. A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to b
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference
2. Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
3. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
4. Labopharm amends debt facility agreement with Hercules
5. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
6. Labopharm Reports Results for First Quarter Fiscal 2009
7. Labopharm announces details for first quarter results conference call and annual meeting
8. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
9. Labopharm to present at Cowen 29th Annual Health Care Conference
10. Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
11. Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 02, 2015 National Autism Resource ... marketing, web design and development agency, to launch its ... National Autism Resources’ new website is designed ... all ages diagnosed with autism. The site will expand ... an array of resources, from easy to understand information ...
(Date:6/2/2015)... LUSAKA, Zambia (PRWEB) June 02, 2015 ... agricultural businesses, today opened a new seed warehouse and ... capacity and meet farmer demand for both local and ... Africa. , “Zambia could emerge as the breadbasket ... fostered,” said Worede Woldemariam, East and South Central Africa ...
(Date:6/2/2015)... 2015 ODU , a ... connector solutions and cable assemblies, is announcing its ... the US market. , ODU MINI-SNAP® ... The self- securing circular connector solution is ideal ... require significant customization such as: sensor devices, data ...
(Date:6/2/2015)... PhishLine, LLC today announced it will ... Suite 125 in Waukesha, Wisconsin 53186. The ... of operations for PhishLine’s current corporate staff and ... Mark Chapman, Founder and President, commented “PhishLine is ... customers adopt our market leading service to address ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 The ... for non-GMO products made according to rigorous best ... products are produced in compliance with the Non-GMO ... all GMO risk ingredients, facility inspections and an ... for GMO avoidance. , “Savoury Systems is and ...
Breaking Medicine News(10 mins):Health News:National Autism Resources Launches New Website, Delivering More Products and Services 2Health News:National Autism Resources Launches New Website, Delivering More Products and Services 3Health News:Investing in Infrastructure Critical to Advancing Food Security in Zambia 2Health News:Investing in Infrastructure Critical to Advancing Food Security in Zambia 3Health News:ODU Announces ODU MINI-SNAP® - Advanced Circular Connector Solution for Highly Customizable Applications 2Health News:PhishLine, LLC Announces New Corporate Headquarters 2Health News:Savoury Systems International Receives Non-GMO Project Verification Continuing its Commitment to Provide Customers with Clean Label Ingredients 2
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) and Autoliv ... Inc. (NYSE: ALV and SSE: ALIV),today ... supply,agreement for chemical heat packages, a key component ... easy to use single-dose,Staccato devices each contain a ...
... Behaviors Found in Boys, Not Girls, SEATTLE, Nov. ... 2 and 5 years of age is clearly linked ... age 7 to 9,according to a new study published ... Christakis, MD, MPH, and Frederick,Zimmerman, PhD, both of Seattle ...
... asthma among young inner-city children appears to be more unpredictable ... is a wise move as a hedge against dangerous flare-ups ... a study from the Johns Hopkins Childrens Center. Current asthma ... diagnosis, but six months may be too long for many ...
... explain why the supposedly natural act of aging is by ... , In a study to be presented Nov. ... in Orlando, Fla., the Hopkins team analyzed more than a ... minute changes in the hearts of 5,004 men and women, ...
... Doctors need to do more to erase racial disparities, study ... high blood pressure among heart failure patients vary widely by ... team at the Medical University of South Carolina, Mt. Pleasant, ... failure patients, but experts know little about actual rates of ...
... including one from the Framingham Heart Study,link PAT signal with ... ... Fla., Nov. 4 Itamar Medical announced,confirmation of PAT technology ... PAT technology, Itamar Medical will now,promote clinical use in the ...
Cached Medicine News:Health News:Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System 2Health News:Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System 3Health News:Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System 4Health News:Watching Violent TV at Pre-School Age Linked to Aggression in Young Boys 2Health News:Watching Violent TV at Pre-School Age Linked to Aggression in Young Boys 3Health News:Watching Violent TV at Pre-School Age Linked to Aggression in Young Boys 4Health News:Urban kids with asthma need more frequent check-ups, Hopkins study suggests 2Health News:Aging heart changes shape, shrinks and loses pumping function too 2Health News:Aging heart changes shape, shrinks and loses pumping function too 3Health News:Poorer Blood Pressure Control in Blacks With Heart Failure 2Health News:New Research Released at AHA Confirms Itamar's PAT Technology to Diagnose Early Cardiovascular Disease 2
(Date:6/2/2015)... 2015 ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... from the U.S. Food and Drug Administration (FDA) of ... Oral Solution 5mg/5mL. Trailing twelve-month sales for the product ... competitors. ANI expects to begin shipping to its customers ... and CEO of ANI Pharmaceuticals, stated, "This ANDA represents ...
(Date:6/2/2015)... 2, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... studies performed with ORMD-0801, its orally ingestible insulin capsule ... the poster sessions in the ADA 75 th ... Boston . The poster will be attended by ...
(Date:6/2/2015)... 2, 2015  CytRx Corporation (NASDAQ: CYTR ), ... today announced that it has reached an agreement to ... Delaware Court of Chancery, which names ... former directors and officers, and names the Company as ... In re CytRx Corp. Stockholder Derivative Litigation , C.A. ...
Breaking Medicine Technology:ANI Pharmaceuticals Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL 2ANI Pharmaceuticals Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL 3Oramed to Present at the American Diabetes Association 75th Scientific Sessions 2Oramed to Present at the American Diabetes Association 75th Scientific Sessions 3Oramed to Present at the American Diabetes Association 75th Scientific Sessions 4CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 3CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 4
... Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE—News) ("Ampio" or the ... uses for previously approved drugs and new molecular ... agreement to acquire certain rights relating to a ... that can be used worldwide to elevate the ...
... Nearly one million doses of the NOBIVAC Canine ... shelters and rescue groups in 49 states as part ... between the Petfinder.com Foundation and Merck Animal Health.   The ... the canine influenza virus (CIV), better known as dog ...
Cached Medicine Technology:Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology 2Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology 3Nearly 1,400 Animal Shelters and Rescues, in Partnership With Veterinarians, Build Community Immunity Against Canine Influenza 2
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Made exclusively from LactoSorb® Resorbable Copolymer....
... of 25% Hydroxy-Apatite (HA) and 75% Poly-L ... the fixation strength of a titanium interference ... bone. Our wedge design makes it ideal ... increases the healing characteristic of the bone ...
Medicine Products: